PWYLLGOR ANSAWDD, DIOGELWCH A SICRHAU PROFIOD QUALITY, SAFETY AND EXPERIENCE ASSURANCE COMMITTEE

| DYDDIAD Y CYFARFOD: | 07 July 2020 |
|------------------------|--|
| DATE OF MEETING: | |
| TEITL YR ADRODDIAD: | Corporate Risk Report |
| TITLE OF REPORT: | |
| | Andrew Carruthers, Executive Director of Operations |
| | Alison Shakeshaft, Executive Director of Therapies & Health Sciences |
| CYFARWYDDWR ARWEINIOL: | Ros Jervis, Executive Director Of Public Health |
| LEAD DIRECTOR: | Mandy Rayani, Executive Director of Nursing, Quality |
| | and Patient Experience |
| | Steve Moore, Chief Executive Officer |
| SWYDDOG ADRODD: | Joanne Wilson, Board Secretary |
| REPORTING OFFICER: | Charlotte Beare, Head of Assurance and Risk |

| Pwrpas yr Adroddiad (dewiswch fel yn addas) |
|---|
| Purpose of the Report (select as appropriate) |
| Er Sicrwydd/For Assurance |


ADRODDIAD SCAA SBAR REPORT

Sefyllfa / Situation

The Committee is asked to request assurance from Executive Directors that the corporate risks in the attached report are being managed effectively, prior to submission to the Board in July 2020.

Cefndir / Background

Effective risk management requires a 'monitoring and review' structure to be in place to ensure that risks are effectively identified and assessed and that appropriate controls and responses are in place.



(Risk Management Process, ISO 31000)

The Board's Committees are responsible for the monitoring and scrutiny of <u>corporate level</u> risks within their remit. They are responsible for:

- Seeking assurance on the management of principal risks on the Board Assurance
 Framework (BAF)/Corporate Risk Register (CRR) and providing assurance to the Board
 that risks are being managed effectively and report areas of significant concern, for
 example, where risk appetite is exceeded, lack of action, etc.
- Reviewing principal and operational risks over tolerance and where appropriate recommend the 'acceptance' of risks that cannot be brought within HDdUHB's risk appetite/tolerance to the Board.
- Provide annual reports to Audit & Risk Assurance Committee (ARAC) on the effectiveness of the risk management process and management of risks within its remit.
- Identity through discussions any new/emerging risks & ensure these are assessed by management.
- Signpost any risks outside of its remit to the appropriate UHB Committee.
- Use risk registers to inform meeting agendas.

These risks have been identified by individual Directors via a top down and bottom up approach and are either:

- Associated with the delivery of the Health Board objectives; or
- Significant operational risks escalated that are of significant concern and need corporate oversight and management.

Each risk on the CRR has been mapped to a Board level Committee to ensure that risks on the CRR are being managed appropriately, taking into account the gaps, planned actions and agreed tolerances, and to provide assurance to the Board through their update report on the management of these risks.

The Board has delegated a proportion of its role of scrutiny of assurances to its Committees to make the most appropriate and efficient use of expertise. Therefore, Committees should also ensure that assurance reports relevant to the principal risks are received and scrutinised, and an assessment made as to the level of assurance it provides, taking into account the validity and reliability i.e. source, timeliness, methodology behind its generation and its compatibility with other assurances. This will enable the Board to place greater reliance on assurances, if they are confident that they have been robustly scrutinised by one of its Committees; and provide them with greater confidence about the likely achievement of strategic objectives, as well as providing a sound basis for decision-making. It is the role of Committees to challenge where assurances in respect of any component are missing or inadequate. Any gaps should be escalated to the Board.

The Board and Committee cycle has been amended in response to COVID-19, and it was agreed at the Board on 16th April 2020 that the CRR is reviewed and agreed by Executive Directors on a monthly basis prior to Board, with the Quality, Safety and Experience Assurance Committee (QSEAC) retaining scrutiny role of risks aligned to the safety and quality of services. A new COVID-19 theme has been added to Datix which can be selected for existing and new risks as appropriate.

The process for risk reporting and monitoring within the UHB is outlined at Appendix 1.

Asesiad / Assessment

The QSEAC Terms of Reference reflect the Committee's role in providing assurance to the Board that principal risks are being managed effectively by the risk owners (Executive Leads).

The Terms of Reference state that:

5.2 Seek assurance on the management of principal risks within the Board Assurance Framework (BAF) and Corporate Risk Register (CRR) allocated to the Committee and provide assurance to the Board that risks are being managed effectively and report any areas of significant concern e.g. where risk tolerance is exceeded, lack of timely action.

Following the Board in April 2020, Executive Directors were asked to consider their existing corporate risks in light of COVID-19 pandemic. They were asked to:

- Reflect the impact of COVID-19 on existing risks and how this may reduce/increase the level of risk facing the Health Board.
- De-escalate risks that do not reflect the current priorities of the Health Board.
- Assess new and emerging risks relating to the potential impact of COVID-19 planning and management.
- Consider risks from their Directorate risk registers as to whether they should be considered for escalation to CRR.

There are 12 risks currently aligned to QSEAC (out of the 25 that are currently on the CRR) as the potential impacts of the risks relate to the safety of patients, quality of services and patient outcomes. A summary of corporate risks can be found at Appendix 2.

Each of these risks have been entered onto a 'risk on a page' template which includes information relating to the strategic objective, controls, assurances, performance indicators and action plans to address any gaps in controls and assurances. These can be found at Appendix 3.

Changes since the previous QSEAC meeting (June 2020):

The Committee is asked to seek assurance from risk owners (Executive Directors) that each risk is being managed effectively and will be brought within the UHB tolerance.

Below is a summary of changes since the previous report to QSEAC:

| Total number of risks | 12 |
|---------------------------|----|
| New / escalated risks | 0 |
| De-escalated/Closed risks | 0 |
| Increase in risk score ↑ | 0 |
| Reduction in risk score ↓ | 1 |
| No change in risk score → | 11 |

See note 1 See note 2

Note 1 - Increase/Decrease in Current Risk Score

Since the previous report to QSEAC in June 2020, there have been the following changes to current risk scores.

| Risk Reference & Title | Previous Risk Score (Dec-19) | Risk Score May-20 | Date | Update |
|-------------------------|---------------------------------------|-------------------------|----------|---------------------------------|
| Risk 117 - Delays in | 3x5=15 | 2x5=10 | 08/06/20 | The UHB has previously |
| transfers to tertiary | | | | experienced delays in |
| centres for urgent | | | | transferring patients to |
| cardiac investigations, | | | | Swansea Bay UHB (SBUHB) |
| treatment and surgery | | | | tertiary service for a range of |

| cardiac investigations, treatments and surgery. The historic risk specifically associated with transfer delays for N-STEMI patients (NICE: 'within 72 hours' reduced on development of the NSTEMI Treat and Repatriate service. The risk has been reduced given a reduced level of demand (reduced acute hospital presentation, reduced referrals from primary care, reduced cardiology outpatient activity) on account of COVID-19. The Cardiology Service has identified 'reduced patient |
|---|
| from primary care, reduced cardiology outpatient activity) on account of COVID-19. The Cardiology Service has |
| presentation/primary care referral' and 'reduced Cardiology Outpatient activity' as two separate risks to manage this change. |

Note 2 - No change in risk score

| Risk Reference & Title | Previous Risk Score (Dec20) | Risk Score May-20 | Date of Review | Update |
|--|--------------------------------------|-------------------------|-------------------|--|
| Risk 628 - Fragility of therapy provision across acute and community services | 4x4=16 | 4x4=16 | 02/06/20 | There are significant gaps in the therapy service provision across acute, community and primary care, the reasons for this are described in the cause section of the risk. Impact to service provision by COVID-19 will add an additional challenge to workforce models. Across all therapy services, current demand does not align to current capacity and whilst this is being managed as far as possible by the controls in place, it is not sustainable. |
| Risk 684 - Lack of agreed replacement programme for radiology equipment across UHB | 4x4=16 | 4x4=16 | 15/05/20 | Whilst activity has decreased due to COVID-19, scanning of COVID-19 patients requires more time than non-COVID patients, which may become an issue as requests for diagnostics for non-COVID-19 |

| | | T. | | |
|--|--------|---------------------|----------|--|
| | | | | patients increase as other |
| | | | | services resume. |
| | | | | Commissioning of agreed |
| | | | | equipment has also been |
| | | | | delayed as a result of COVID- |
| | | | | 19 and this remains |
| 700 Failure to recet its | 424-40 | 4>-4-4C | 40/05/00 | dependent external factors. |
| 733 - Failure to meet its | 4x4=16 | 4x4=16 | 12/05/20 | This risk reflects that due to |
| statutory duties under Additional Learning | | | | COVID-19, the organisational focus, as well as resources, |
| Needs and Education | | | | have moved away from |
| Tribunal (ALNET) Act | | | | preparing for the |
| (Wales) 2018 by Sept | | | | implementation of the ALNET |
| 2020 | | | | Act. |
| 810 - Poor quality of | 3x4=12 | 3x4=12 | 01/06/20 | This risk was entered on the |
| care within the | 3A7-12 | 0∧ 4 −1Z | 01/00/20 | CRR prior to COVID-19 and |
| unscheduled care | | | | reflected the risk within the |
| pathway | | | | unscheduled care system. |
| patiway | | | | Whilst the current risk has |
| | | | | reduced during COVID-19 |
| | | | | from 20 to 12, potentially |
| | | | | influenced by reduced |
| | | | | demand for emergency care at |
| | | | | our Emergency Department |
| | | | | facilities. Ambulance delays |
| | | | | have reduced to their lowest |
| | | | | recorded level since July |
| | | | | 2017. Where delays occur at |
| | | | | the present time, these |
| | | | | predominantly relate to the |
| | | | | challenges of ensuring |
| | | | | patients with known / |
| | | | | suspected COVID-19 |
| | | | | symptoms are cared for in the |
| | | | | most appropriate environment |
| | | | | for their (and other patients') |
| | | | | needs. The risk is not |
| | | | | completely resolved as |
| | | | | pressure on non-COVID-19 |
| | | | | GREEN capacity continues on |
| | | | | some sites and the situation |
| | | | | remains under review. Work |
| | | | | to implement the planned |
| | | | | actions continues to ensure |
| | | | | the Health Board is prepared |
| | | | | for Winter 2020/21 and to help prevent the return of extreme |
| | | | | pressures in the post COVID- |
| | | | | 19 period. |
| Risk 750 - Lack of | 3x4=12 | 3x4=12 | 05/05/20 | Despite improvement through |
| substantive middle | 0A4-1Z | υλ 4 -12 | 00/00/20 | locum staff being secured, the |
| grade doctors affecting | | | | middle grade rota remains |
| Emergency Department | | | | under constant review and |
| Linergency Department | | | | under constant review and |

| (ED): NACH | | | | |
|--|--------|--------|----------|--|
| (ED) in Withybush General Hospital | | | | management as the department are fully reliant on |
| (WGH) | | | | temporary staff. There are |
| | | | | adverts for 4 middle grade |
| | | | | doctors currently out to advert. |
| Risk 91 - Insufficient | 3x4=12 | 3x4=12 | 21/05/20 | Whilst there has been a |
| number of Consultant | | | | temporary reduction in overall |
| Cellular Pathologists to meet 14 day timescale | | | | demand, there are plans to recommence work, e.g. |
| set out in the new | | | | endoscopy and some cancer |
| Single Cancer Pathway | | | | surgery which will impact on |
| | | | | the Cellular pathology |
| | | | | workload. In addition, working |
| | | | | arrangements in the team |
| | | | | have been changed in |
| | | | | response to COVID-19. Also due to the vacancies, the |
| | | | | service is still unable to |
| | | | | support the tumour specific |
| | | | | cancer Multi-disciplinary Team |
| | | | | (MDT) meetings. It is |
| | | | | anticipated that "digital |
| | | | | pathology" will probably impact on the way Consultants |
| | | | | work in the future when this is |
| | | | | rolled out nationally (timeline |
| | | | | TBC). |
| 855 - Risk that UHB's | 3x4=12 | 3x4=12 | 19/05/20 | This risk reflects the risk to |
| normal business will not | | | | patients who will be affected |
| be given sufficient focus | | | | by services being scaled back |
| | | | | or suspended as part of the response to COVID-19. The |
| | | | | Health Board has submitted its |
| | | | | response to the NHS Wales |
| | | | | Operating Framework for |
| | | | | Quarter 1, which outlines the |
| | | | | need to maintain essential |
| | | | | services and retain flexibility to |
| | | | | respond to changes of transmission rates of COVID- |
| | | | | 19 in the community. |
| | | | | Response to Quarter 2 |
| | | | | Operating Framework |
| | | | | currently being developed. |
| Risk 129 - Ability to | 4x3=12 | 4x3=12 | 15/05/20 | The risk has been recently |
| deliver a GP Out of | | | | reduced as the COVID-19 |
| Hours (OOH) Service for Hywel Dda patients | | | | pandemic combined with the temporary overnight service |
| IOI Frywer Dua patierits | | | | changes (reduction of 5 to 3 |
| | | | | bases with a new OOH/MIU |
| | | | | GP pathway in PPH) has |
| | | | | brought some respite to the |
| | | | | fragility outlined above. |

| 634 - Overnight theatre provision in Bronglais General Hospital (BGH) | 2x5=10 | 2x5=10 | 01/06/20 | However any lifting of lock down measures as well as possible impacts on in-hours provision is likely to result in a fragile workforce position once again. The rationale that was placed around the need for service improvement and modernisation needs to be progressed. Significant sickness levels amongst salaried GP workforce have been resolved however, in the event of a second wave of COVID-19, there are a number of staff who may become unavailable to work due to health-related vulnerabilities. The APP model continues to provide significant resilience (when available) in terms of supplementary resource. Discussions to assess potential for expansion of this model have now commenced but no decision has yet been reached. This risk was reviewed by the service and has been reduced as a number of actions have been implemented and there have been no reported incidents. The BGH unit is classed as an obstetric unit with modified criteria for delivery, with mothers assessed as high risk of complications managed through the maternity unit in Carmarthen. Resolution of the process to remove compensatory rest days was paused during the COVID-19 and will form part of the Quarter 2 plan. Staff and union representatives have been informed. |
|---|--------|--------|----------|--|
| 635 - No deal Brexit affecting continuity of patient care | 4x2=8 | 4x2=8 | 26/05/20 | The risk score has reduced to reflect on-going work, and plans at local, regional and national levels, and recent resilience measures adopted by the organisation in |

| | | | | response to COVID-19. The compounding effect of a Brexit no-deal scenario with winter plans, maintaining the COVID-19 response and the increasing concern regarding the fragility of the independent social care sector requires the likelihood to remain at 4 however the impact score has been reduced to 2 to reflect the additional resilience at a national, regional and local level due to COVID-19. |
|--|-------|-------|----------|--|
| 853 - Risk that Hywel Dda's response to COVID-19 will be Insufficient to manage demand | 1x5=5 | 1x5=5 | 19/05/20 | This risk reflects that Health Board would not be able to manage an increase in demand in terms of bed space, workforce and equipment/consumables and to reflect the potential quality and safety impacts. This risk is within the Health Board risk tolerance as based on estimated COVID-19 demand and the planning undertaken to respond to COVID-19, the likelihood of this risk has been reduced from 3 to 1. |

Argymhelliad / Recommendation

The Committee is asked to seek assurance that:

- All identified controls are in place and working effectively.
- All planned actions will be implemented within stated timescales and will reduce the risk further and/or mitigate the impact, if the risk materialises.
- Challenge where assurances are inadequate.

This in turn will enable the Committee to provide the necessary assurance to the Board, through its Committee Update Report, that the UHB is managing these risks effectively.

| Amcanion: (rhaid cwblhau) Objectives: (must be completed) | |
|---|---|
| Committee ToR Reference: Cyfeirnod Cylch Gorchwyl y Pwyllgor: | 5.2 Seek assurance on the management of principal risks within the Board Assurance Framework (BAF) and Corporate Risk Register (CRR) allocated to the Committee and provide assurance to the Board that risks are being managed effectively and report any areas of significant concern e.g. where risk tolerance is exceeded, lack of timely action. |

| Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score: | Contained in report |
|--|---|
| Safon(au) Gofal ac lechyd: Health and Care Standard(s): | Governance, Leadership and Accountability |
| Nodau Gwella Ansawdd: Quality Improvement Goal(s): | All Quality Improvement Goals Apply |
| Amcanion Strategol y BIP: UHB Strategic Objectives: | All Strategic Objectives are applicable |
| Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Statement | Not Applicable |

| Gwybodaeth Ychwanegol: Further Information: | |
|--|--|
| Ar sail tystiolaeth: Evidence Base: | Underpinning risk on the Datix Risk Module from across the UHB's services reviewed by risk leads/owners |
| Rhestr Termau: Glossary of Terms: | Current Risk Score - Existing level of risk taking into account controls in place |
| | Target Risk Score - The ultimate level of risk that is desired by the organisation when <u>planned</u> controls (or actions) have been implemented |
| | Tolerable risk – this is the level of risk that the Board agreed for each domain in September 2018 – Risk Appetite Statement |
| Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y Pwyllgor Ansawdd, Diogelwch a Sicrhau Profiod: Parties / Committees consulted prior to Quality, Safety and Experience Assurance Committee: | N/A |

| Effaith: (rhaid cwblhau) | |
|-----------------------------|---|
| Impact: (must be completed) | |
| Ariannol / Gwerth am Arian: | No direct impacts from report however impacts of each |
| Financial / Service: | risk are outlined in risk description. |

| Ansawdd / Gofal Claf: Quality / Patient Care: | No direct impacts from report however impacts of each risk are outlined in risk description. |
|--|--|
| Gweithlu: Workforce: | No direct impacts from report however impacts of each risk are outlined in risk description. |
| Risg: Risk: | No direct impacts from report however organisations are expected to have effective risk management systems in place. |
| Cyfreithiol: Legal: | No direct impacts from report however proactive risk management including learning from incidents and events contributes towards reducing/eliminating recurrence of risk materialising and mitigates against any possible legal claim with a financial impact. |
| Enw Da: Reputational: | Poor management of risks can lead to loss of stakeholder confidence. Organisations are expected to have effective risk management systems in place and take steps to reduce/mitigate risks. |
| Gyfrinachedd: Privacy: | No direct impacts |
| Cydraddoldeb: Equality: | Has EqIA screening been undertaken? No Has a full EqIA been undertaken? No |

Appendix 1 – Committee Risk Reporting Structure

